成功血管内治疗后动脉内替奈普酶治疗急性卒中:ANGEL-TNK随机临床试验
这项在中国19个中心开展的前瞻性、开放标签、盲法终点随机试验,纳入发病4.5至24小时的急性前循环大血管闭塞患者,成功血管内再通后随机接受动脉内替奈普酶0.125 mg/kg(n=126)或标准药物治疗(n=129)。90天mRS 0-1分比例动脉内替奈普酶组40.5% vs 标准药物组26.4%(RR 1.44,95%CI 1.06-1.95;P=.02),7个次要疗效终点均无显著差异,sICH与90天死亡率无显著差异。
要点
- 成功血管内再通后动脉内替奈普酶0.125 mg/kg使90天mRS 0-1分比例达40.5%,标准药物组为26.4%(RR 1.44,95%CI 1.06-1.95;P=.02)。
- 7个预设次要疗效终点均未显示显著差异。
- 48小时内sICH动脉内替奈普酶组5.6% vs 标准药物组6.2%(RR 0.95,95%CI 0.36-2.53;P=.92),90天死亡率21.4% vs 21.7%(RR 0.76,95%CI 0.40-1.43;P=.78)。
核心结论
- 在发病4.5至24小时的急性大血管闭塞患者中,成功取栓后动脉内替奈普酶在90天获得优良神经功能结局的可能性更高,且未增加sICH或死亡风险。
- 由于次要疗效分析均未支持主要发现,需进一步试验确认结果。
研究设计与样本
- 前瞻性、开放标签、盲法终点随机试验,在中国19个中心开展,招募时间为2023年2月16日至2024年3月23日,末次随访为2024年7月4日。
- 纳入发病4.5至24小时的急性前循环大血管闭塞患者,成功血管内再通(eTICI 2b及以上)后随机接受动脉内替奈普酶0.125 mg/kg(n=126)或标准药物治疗(n=129)。
- 共256例患者随机(中位[IQR]年龄71.6[61.3-79.2]岁;女性113例[44.1%]),255例(99.6%)完成试验。
主要发现
- 90天mRS 0-1分比例动脉内替奈普酶组40.5%(n=51)vs 标准药物组26.4%(n=34)(相对危险度1.44[95%CI 1.06-1.95];P=.02)。
- 7个预设次要疗效终点均未显示显著差异。
- 48小时内sICH动脉内替奈普酶组5.6% vs 标准药物组6.2%(相对危险度0.95[95%CI 0.36-2.53];P=.92)。
- 90天死亡率动脉内替奈普酶组21.4% vs 标准药物组21.7%(相对危险度0.76[95%CI 0.40-1.43];P=.78)。
关键数值与推荐
- 主要终点为90天优良结局,定义为改良Rankin量表(mRS)评分0至1分(范围0[无症状]至6[死亡])。
- 次要疗效终点共7个,包括90天mRS 0-1分、90天mRS评分、90天mRS 0-2分、90天mRS 0-3分、36小时美国国立卫生研究院卒中量表评分0-1分或改善≥10分、90天欧洲生活质量视觉模拟量表评分、24小时最大体积时间>6秒、梗死核心体积较基线变化。
- 安全性终点共3个,包括48小时内症状性颅内出血(sICH)、48小时内任何颅内出血、90天内全因死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 由于次要疗效分析均未支持主要发现,需进一步试验确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The role of intra-arterial tenecteplase for acute large vessel occlusion (LVO) stroke after successful endovascular therapy is uncertain. OBJECTIVE: To assess the efficacy and safety of intra-arterial tenecteplase in patients with successful endovascular therapy (defined as a score on the expanded Thrombolysis in Cerebral Infarction [eTICI] scale of 2b to 3) after endovascular therapy. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, open-label, blinded end point, randomized trial. Recruitment took place between February 16, 2023, and March 23, 2024, with final follow-up on July 4, 2024. The study was conducted across 19 centers in China. Patients with acute anterior circulation LVO treated between 4.5 and 24 hours from the time that the patient was last known to be well were included. INTERVENTION: After successful endovascular recanalization, defined as eTICI 2b or greater, patients were randomized to receive intra-arterial tenecteplase at 0.125 mg/kg (n = 126) or standard medical treatment (n = 129). MAIN OUTCOMES AND MEASURES: The primary end point was excellent outcome at 90 days, defined as modified Rankin Scale (mRS) score of 0 to 1 (range, 0 [no symptoms] to 6 [death]). There were a total of 7 secondary efficacy end points (mRS score of 0-1 at 90 days, mRS score at 90 days, mRS score of 0-2 at 90 days, mRS score of 0-3 at 90 days, National Institutes of Health Stroke Scale score of 0-1 or improved ≥10 points at 36 hours, European Quality of Life Visual Analogue Scale score at 90 days, time to maximum volume > 6 s at 24 hours, and infarct core volume change from baseline) and 3 safety end points, including symptomatic intracranial hemorrhage (sICH) within 48 hours, any intracranial hemorrhage within 48 hours, and all-cause mortality within 90 days. RESULTS: Among 256 patients who were randomized (median [IQR] age, 71.6 [61.3-79.2] years; 113 [44.1%] females), 255 (99.6%) completed the trial. The rate of patients with an mRS score of 0 to 1 at 90 days was 40.5% in the intra-arterial tenecteplase group (n = 51) and 26.4% in the standard medical treatment group (n = 34) (relative risk, 1.44 [95% CI, 1.06-1.95]; P = .02). Of 7 prespecified secondary efficacy end points, none showed a significant difference. Intra-arterial tenecteplase after endovascular therapy did not increase the incidence of sICH within 48 hours after treatment compared with standard medical treatment (5.6% vs 6.2%; relative risk, 0.95 [95% CI, 0.36-2.53]; P = .92). Mortality at 90 days was 21.4% with intra-arterial tenecteplase and 21.7% with standard medical treatment (relative risk, 0.76 [95% CI, 0.40-1.43]; P = .78). CONCLUSIONS AND RELEVANCE: In patients with acute LVO presenting between 4.5 and 24 hours of symptom onset, intra-arterial tenecteplase after successful thrombectomy had a greater likelihood of excellent neurological outcome at 90 days without increasing the risk of sICH or mortality. However, because none of the secondary efficacy analyses supported the primary finding, further trials are needed to confirm the results. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05624190.
引用
- Miao Z, Luo G, Song L, et al. Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy: The ANGEL-TNK Randomized Clinical Trial. JAMA. 2025. PMID: 40616323. doi:10.1001/jama.2025.10800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。